Oncotarget: Read All About It!

Oncotarget is a peer-reviewed publication. It is published every week. In it a reader will find the latest discoveries resulting from numerous scientific research on oncology and various other medical-related topics. Its parent is Impact Journals.

The Oncotarget put out its premiere article approximately seven years ago. The Oncotarget has since grown to become a source of publication for literally thousands of peer-reviewed articles. The articles are reported to be generally insightful and are all published in the international language of English and more information click here.

 

Why English?

This decision was made by management in order to ensure that a significantly sizeable part of the planet’s population could read all of the articles. The Oncotarget is officially classified as an “open-access journal.” This basically means that any research scientist or research group involved in scientific research has, in theory, the chance to use this research journal.

 

The Oncotarget Team

Internet sources indicate that Oncotarget’s founders are dedicated, talented, and qualified. They are also reported to have a significant reputation for their research as well. Oncotarget is headed up by the two chief editors professor Mikhail Blagoskloklonny and professor Andre V. Gudkov and learn more about Oncotarget.

 

Oncotarget’s Chief Editors

Oncotarget’s pair of chief editors are respected, popular professors at the Roswell Park Cancer Institute found in Buffalo, New York. Gudkov has actually made noteworthy contributions in the field of cancer therapy and treatment, especially when it comes to molecular targets and the discovery of medications. Blagosklonny himself wrote over 250 scientific articles in several peer-reviewed journals.

 

Submissions And Statistics

The publication’s staff ensures that each submission that is accepted for publication meets a set of high standards concerning qualitative and educational value. In its first year of publication, Oncotarget had an impact factor (IF) of 4.78 and was seen by readers in 493 cities and Oncotarget’s lacrosse camp.

In 2013 Oncotarget was actually registered as receiving the “highest impact factor” of 6.727. Furthermore, it increased its overall circulation to over 30,000 cities. The general reception of the Oncotarget has now multiplied by nearly 100 times since its launch and https://oncotarget.msubmit.net/cgi-bin/main.plex.